Shares of Accenture plc (NYSE:ACN – Get Free Report) have earned a consensus rating of “Moderate Buy” from the twenty-three ...

Despite DeepSeek and Qwen 2.5 disrupting the global tech sector, investors welcomed the impressive Q4 AI revenues from ...

We recently published a list of Kevin O’Leary’s Stock Portfolio: 15 Stock Picks for 2025. In this article, we are going to ...

(HealthDay News) — A blood-based test (Freenome) may provide a new option for colorectal cancer (CRC) screening in the average-risk US population, according to a study presented at the American ...

Accenture (ACN) reachead $380.75 at the closing of the latest trading day, reflecting a +1.69% change compared to its last close.

Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range ...

We recently published a list of 10 AI Stocks on Wall Street’s Radar. In this article, we are going to take a look at where ...

A team from the University of Geneva and Bayer AG present their findings on the on-off retention of oligonucleotides and the ...

In a report released today, Jason Kupferberg from Bank of America Securities maintained a Buy rating on Accenture (ACN – Research Report). The ...

The long-awaited and elusive ceasefire between Israel and Hamas has silenced bombs and halted air raids on the Gaza Strip, ...

Companies in the Technology sector have received a lot of coverage today as analysts weigh in on Accenture (ACN – Research Report) and Itron ...

ACN's vague AI strategy and overvaluation by the market suggest potential revenue struggles, with 2025 growth projections likely to be over-optimistic. The company's earnings are a weak proxy for ...